India Outperforms with High Growth and Low Volatility

India Outperforms with High Growth and Low Volatility

Morgan Stanley’s Chief Asia Equity Strategist Jonathan Garner explains why Indian equities are our most preferred market in Asia.


Read more insights from Morgan Stanley.


----- Transcript -----


Welcome to Thoughts on the Market. I’m Jonathan Garner, Morgan Stanley’s Chief Asia Equity Strategist. Today I’ll discuss why we remain positive on India’s long-term equity story.

It’s Tuesday, the 24th of June at 9am in Singapore.

We’ve had a long-standing bullish outlook on the India economy and its stock market. In the last five years MSCI India has delivered a total return in U.S. dollars of 145 percent versus 94 percent for global equities and just 39 percent for emerging markets. Indian equities are our most preferred market within Asia for three key reasons. First, India’s superior economic and earnings growth. Second, lower exposure to trade tariffs. And third, a strong domestic investor base. And all of this adds up to structural outperformance not just in Asia but indeed globally, and with significantly lower volatility than peer group markets.

So let’s dive deeper. To start with – the macroeconomic backdrop. We expect India to account for 20 percent of overall incremental global GDP growth in the coming decade. Manufacturing competitiveness is improving thanks to bolstered infrastructure in power, ports, roads, freight transport systems as well as investments in social infrastructure such as water, sewage and hospitals.

Additionally, India's growing middle class offers market opportunities to companies across many product categories. There’s robust domestic consumption, a strong investment cycle led by public and private capital expenditure and continuing structural reforms, including in the legal sphere. GDP growth in the first quarter was more than 7 percent and our team expects over 6 percent in the medium term, which would be by far the highest of the major economies.

Furthermore, we continue to expect robust corporate earnings growth. Since the end of COVID, MSCI India has delivered around 12 percent per annum [U.S.] dollar earnings per share growth versus low single digits for Emerging Markets overall. And we forecast 14 percent and 16 percent over the next two fiscal years. Growth drivers in the short term include an emerging private CapEx cycle, re-leveraging of corporate balance sheets, and a structural rise in discretionary consumption – signaling increased business and consumer confidence, after last year’s elections.

Another key reason that we’re positive on India currently is its lower-than-average vulnerability to ongoing trade and tariff disputes between the U.S. and its trade partners. Exports of goods to the U.S. amount to only 2 percent of India’s GDP versus, for example, 10 percent in Thailand or 14 percent in Taiwan. And India’s total goods exports are only around 12 percent of GDP. Moreover, for the time being, India’s very large services sector’s exports are not exposed to tariff actions, and are actually early beneficiaries of AI adoption.

Finally, India’s strong individual stock ownership means that there’s persistent retail buying, which underpins the equity market. Systematic Investment Plan (SIP) flows driven by a young urbanizing population are making new highs, and in May amounted to over U.S.$3 billion. They provide consistent capital inflows. That means that this domestic bid on stocks is unlikely to fade anytime soon.

This provides a strong foundation for the market and supports valuations which are slightly above emerging market averages. It also means that its market beta to global equities are low and falling, approximately 0.4 versus 1.1 ten years ago. And price volatility is well below other emerging markets. All told, making India an attractive play in volatile times.

Thanks for listening. If you enjoy the show, please leave us a review wherever you listen and share Thoughts on the Market with a friend or colleague today.

Episoder(1574)

U.S. Consumer: What’s Coming for Spending in 2023?

U.S. Consumer: What’s Coming for Spending in 2023?

Though U.S. consumer spending was surprisingly robust in 2022, this poses both new and continuing challenges as households draw down their excess savings.----- Transcript -----Michelle Weaver: Welcome...

14 Feb 20237min

Seth Carpenter: Can Inflation Continue To Come Down?

Seth Carpenter: Can Inflation Continue To Come Down?

Inflation was a key topic in a recent meeting at the Brookings Institution. While it has trended downward recently, the details are critical to tracking the path ahead.----- Transcript -----Welcome to...

13 Feb 20234min

Andrew Sheets: The Complexities of Market Risk

Andrew Sheets: The Complexities of Market Risk

While the risk of economic contraction has lessened in a few regions, is the story of recession and market risk being oversimplified?----- Transcript -----Welcome to Thoughts on the Market. I'm Andrew...

10 Feb 20232min

Vishy Tirupattur: A Change in Fed Policy Expectations

Vishy Tirupattur: A Change in Fed Policy Expectations

With the latest U.S. employment report showing unexpected resilience in the labor market, what happens now for the Fed and the policy tightening cycle?----- Transcript -----Welcome to Thoughts on the ...

9 Feb 20233min

Michael Zezas: The State of U.S. Policy

Michael Zezas: The State of U.S. Policy

Following last night’s State of the Union Address by President Biden, what are some signals from the speech that investors should consider?----- Transcript -----Welcome to Thoughts on the Market. I'm ...

8 Feb 20232min

Latin America Economy: The Possibility of Opportunity in 2023

Latin America Economy: The Possibility of Opportunity in 2023

As the outlook for 2023 shows emerging markets looking better positioned than developed markets, how is Latin America faring in this more optimistic story? Chief Latin American Equity Strategist Gui P...

7 Feb 20238min

U.S. Pharmaceuticals: The Future of Genetic Medicine

U.S. Pharmaceuticals: The Future of Genetic Medicine

As new gene therapies are researched, developed and begin clinical trials, what hurdles must genetic medicine overcome before these therapies are commonly available? Head of U.S. Pharmaceuticals Teren...

6 Feb 20237min

Andrew Sheets: Where Could Market Strength Persist?

Andrew Sheets: Where Could Market Strength Persist?

After a year of falling assets, 2023 has started strong for global markets. Chief Cross-Asset Strategist Andrew Sheets outlines which markets could sustain their momentum.----- Transcript -----Welcome...

3 Feb 20233min

Populært innen Business og økonomi

stopp-verden
lydartikler-fra-aftenposten
dine-penger-pengeradet
rss-penger-polser-og-politikk
rss-borsmorgen-okonominyhetene
e24-podden
pengepodden-2
finansredaksjonen
utbytte
livet-pa-veien-med-jan-erik-larssen
pengesnakk
morgenkaffen-med-finansavisen
okonomiamatorene
rss-sunn-okonomi
stormkast-med-valebrokk-stordalen
lederpodden
liberal-halvtime
rss-investering-gjort-enkelt
tid-er-penger-en-podcast-med-peter-warren
rss-markedspuls-2